Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts.
Henry Li
Employment or Leadership Position - Crown Bioscience
Dawei Chen
Employment or Leadership Position - Crown Bioscience
Sheng Guo
Employment or Leadership Position - Crown Bioscience
Jie Cai
Employment or Leadership Position - Crown Bioscience
Yiyou Chen
Consultant or Advisory Role - Crown Bioscience
Stock Ownership - Crown Bioscience
Jean-Pierre Wery
Employment or Leadership Position - Crown Bioscience
Stock Ownership - Crown Bioscience